Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 1.7M | 7.2% |
| Gross Profit | 1.3M | 18% |
| Cost of Revenue | 3.3M | 0.8% |
| Operating expense | 3.6M | 7.6% |
| Net Income | -2.2M | 235.4% |
| EBITDA | -1.6M | 3.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 21M | 17.8% |
| Total Liabilities | 18M | 10% |
| Total Equity | 3.1M | 61.4% |
| Shares Outstanding | 10M | 7.7% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -770,000 | 53.6% |
| Cash from financing | -2.8M | 41.7% |
EPS
Financial Highlights for Petros Pharmaceuticals in Q3 '24
Petros Pharmaceuticals reported a revenue of 1.7M, which is a 7.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 1.3M, marking a 18% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.3M, a -0.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 3.6M, showing a 7.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.2M, showing a -235.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -1.6M, showing a -3.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Petros Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
